Second malignancies—risk reduction-Reference-Cited by-同舟云学术

Second malignancies—risk reduction

Published:1987-12 Issue:3-4 Volume:14 Page:337-343
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Petru E.,Schmähl D.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference7 articles.

1. Noncarcinogenic chemotherapy with a combination of vincristine, methotrexate and 5-fluorouracil (VMF) in rats;Berger;Int. J. Cancer.,1983

2. Combination chemotherapy as an adjuvant treatment in operable breast cancer;Bonadonna;New Engl. J. Med.,1976

3. Mesna (Natrium-2-mercaptoethansulfonat): Prophylaxe der akuten urotoxischen Nebenwirkungen sowie der karzinogenen Spatfolgen von Cyclophosphamid und Ifosfamid;Brock;Therapiewoche,1982

4. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium-2-mercaptoethane sulfonate (mesna) and disodium 2,2′-dithio-bis-ethane sulfonate (dimesna);Habs;Cancer,1983

5. Carcinogenic activity in rats of combined treatment with cyclophosphamide, methotrexate and 5-fluorouracil;Habs;Int. J. Cancer.,1981

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Stopping Rule for Standard Chemotherapy for Metastatic Breast Cancer: Lessons from a Survey of Maryland Medical Oncologists;Cancer Investigation;1994-01

2. Treatment of vasculitis.;British Journal of Clinical Pharmacology;1993-02

3. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide;Teratogenesis, Carcinogenesis, and Mutagenesis;1993

4. Ifosfamide/Mesna;Drugs;1991-09

5. Die Janusköpfigkeit der Chemotherapie: Eine Stellungnahme zu den Thesen von Abel;Klinische Wochenschrift;1991-01